# US 2022/0031751 A1 · Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031751 A1
- Document ID: US20220031751A1
- Status: Published application
- Kind: A1
- Application number: 17/391,767
- Filed: 2021-08-02
- Published: 2022-02-03
- Earliest claimed: 2020-08-03
- Applicants: Kyverna Therapeutics, Inc.
- Inventors: Mamle Quarmyne; Faye Wu; Jordan Tsai; John Lee; Jeffrey Greve; Joseph Cheng; Meghana Vijayraghavan
- Web page: https://patentgrep.com/patent/US20220031751A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- C07K 16/2818: {against CD28 or CD152}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2501/60: Transcription factors
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This document relates to methods and materials for treating a mammal having an autoimmune disease. For example, materials and methods for producing a T cell comprising a FOXP3 polypeptide. Methods and materials for treating a mammal having an autoimmune disease comprising administering to a mammal having an autoimmune disease an effective amount of a T cell are also provided herein.

## Claims

### Claim 1

A method of producing T regulatory cells, comprising:
(a) contacting a T cell with an effective amount of (i) one or more CD3-stimulation agent(s) in the absence of a CD28 stimulating agent for a first period of time under conditions that allow for stimulation and activation of the T cell, and
(b) introducing into the T cell an effective amount of a nucleic acid sequence encoding a forkhead box protein 3 (FOXP3) polypeptide,
wherein the presence of the nucleic acid sequence in the T cell induces the T cell to develop or further develop one or more characteristics of a T regulatory cell phenotype compared to when the nucleic acid sequence is not present in the T cell.

### Claim 2 (depends on 1)

The method of claim 1, further comprising contacting the T cell with an effective amount of one or more agent(s) that decreases CD28 expression and/or activity.

### Claim 3

A method of producing T regulatory cells, comprising:
(a) contacting a T cell with an effective amount of (i) one or more CD3-stimulation agent(s), and (ii) one or more CD28-stimulation agent(s) for a first period of time under conditions that allow for stimulation and activation of the T cell;
(b) contacting the T cell with an effective amount of one or more agent(s) that decreases CD28 expression and/or activity; and
(c) introducing into the T cell an effective amount of a nucleic acid sequence encoding a forkhead box protein 3 (FOXP3) polypeptide,
wherein the presence of the nucleic acid sequence in the T cell induces the T cell to develop or further develop one or more characteristics of a T regulatory cell phenotype compared to when the nucleic acid sequence is not present in the T cell.

### Claim 4 (depends on 1)

The method of claim 1, further comprising contacting the T cell with an effective amount of interleukin-2 (IL-2) and/or TGF-β for a second period of time under conditions that allow for stabilization of a T regulatory phenotype as compared to when the T cell is not contacted with IL-2 and/or TGF-β for the second period of time.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method does not comprise contacting the T cell with IL-2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method does not comprise contacting the T cell with TGF-β.

### Claim 7 (depends on 1)

The method of claim 1, wherein the method does not comprise contacting the T cell with IL-2 or TGF-β.

### Claim 8 (depends on 1)

The method of claim 1, wherein the one or more CD3-stimulation agent(s) comprises an effective amount of an anti-CD3 antibody.

### Claim 9 (depends on 1)

The method of claim 1, wherein the one or more CD3-stimulation agent(s) comprise a methyl transferase inhibitor.

### Claim 10 (depends on 3)

The method of claim 3, wherein the one or more CD28-stimulation agents comprises an anti-CD28 activating antibody.

### Claim 11 (depends on 3)

The method of claim 3, wherein the one or more agent(s) that decreases CD28 expression and/or activity comprise an anti-CD28 blocking antibody.

### Claim 12 (depends on 2)

The method of claim 2, wherein the one or more agent(s) that decreases CD28 expression and/or activity comprise a small interfering RNA (siRNA) or a short hairpin RNA (shRNA).

### Claim 13 (depends on 12)

The method of claim 12, wherein the siRNA or the shRNA decreases expression of CD28 in a T cell.

### Claim 14

(canceled)

### Claim 15 (depends on 12)

The method of claim 12, wherein the siRNA or shRNA decreases expression of one or more of p85, p110, PIP3, PKB/Akt, mTOR, IκB, GSK3β, NFκB, NFAT, LCK, FYN, and ITK in a T cell.

### Claim at position 16

16-17. (canceled)

### Claim 18 (depends on 2)

The method of claim 2, wherein the one or more agent(s) that decreases CD28 expression and/or activity comprise a small molecule inhibitor of any one of: LCK, FYN, and ITK.

### Claim 19 (depends on 2)

The method of claim 2, wherein the step of contacting of the T cell with an effective amount of one or more agent(s) that decreases CD28 expression and/or activity further comprises removing the one or more agent(s) that decreases CD28 expression and/or activity after about 1 hour to about 60 hours of the first period of time.

### Claim at position 19

20-22. (canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein step (a) is performed before step (b).

### Claim 24 (depends on 1)

The method of claim 1, wherein step (b) is performed before step (a).

### Claim at position 22

25-26. (canceled)

### Claim 27 (depends on 1)

The method of claim 1, wherein the nucleic acid further comprises a nucleic acid sequence encoding one of the one or more agents that decrease CD28 expression and/or activity.

### Claim 28 (depends on 27)

The method of claim 27, wherein the one of the one or more agents that decrease CD28 expression and/or activity is a siRNA or a shRNA.

### Claim at position 25

29-37. (canceled)

### Claim 38 (depends on 1)

The method of claim 1, wherein the T cell is a CD4+ T cell or a CD4+/CD45RA+ T cell.

### Claim 39 (depends on 1)

The method of claim 1, wherein the method further comprises, before step (a):
obtaining the T cell from a patient or obtaining T cells allogenic to the patient.

### Claim 40

(canceled)

### Claim 41 (depends on 1)

A T cell produced by the method of claim 1.

### Claim 42 (depends on 41)

A composition comprising the T cell of claim 41.

### Claim 43

A T cell comprising:
(i) a first nucleic acid sequence encoding a FOXP3 polypeptide; and
(ii) one or more agents that decreases CD28 expression and/or activity, and/or a second nucleic acid sequence encoding a tNGFR polypeptide.

### Claim at position 32

44-55. (canceled)

### Claim 56

A vector comprising (i) a first nucleic acid sequence encoding a FOXP3 polypeptide and (ii) a second nucleic acid sequence encoding a siRNA or a shRNA that decreases CD28 expression and/or activity, or a tNGFR polypeptide.

### Claim at position 34

57-61. (canceled)

### Claim 62

A vector comprising a first nucleic acid sequence encoding a FOXP3 polypeptide, a second nucleic acid sequence encoding a siRNA or a shRNA that decreases CD28 expression and/or activity, and a third nucleic acid sequence encoding a tNGFR polypeptide.

### Claim at position 36

63-71. (canceled)

### Claim 72 (depends on 41)

A method of treating an autoimmune disease or disorder in a patient comprising administering a T cell of claim 41.

### Claim at position 38

73-76. (canceled)

### Claim 77

A method of transducing a T cell, comprising:
(a) contacting a T cell with an effective amount of (i) one or more CD3-stimulation agent(s) in the absence of a CD28 stimulating agent for a first period of time under conditions that allow for stimulation and activation of the T cell, and
(b) introducing into the T cell an effective amount of a nucleic acid sequence encoding one or more polypeptides operatively linked to a promoter active in T cells, thereby transducing the T cell.

### Claim 78 (depends on 77)

The method of claim 77, further comprising contacting the T cell with an effective amount of one or more agent(s) that decreases CD28 expression and/or activity.

### Claim 79

A method of transducing a T cell, comprising:
(a) contacting a T cell with an effective amount of (i) one or more CD3-stimulation agent(s), and (ii) one or more CD28-stimulation agent(s) for a first period of time under conditions that allow for stimulation and activation of the T cell;
(b) contacting the T cell with an effective amount of one or more agent(s) that decreases CD28 expression and/or activity; and
(c) introducing into the T cell an effective amount of a nucleic acid sequence encoding one or more polypeptides operatively linked to a promoter active in T cells, thereby transducing the T cell.

### Claim at position 42

80-113. (canceled)
